On July 10, PegBio (02565.HK) surged 38.16% in regular trading, reaching HKD 7.64 per share, with turnover of HKD 530 million. The stock opened sharply higher and continued to strengthen throughout the session.

The rally was driven by the announcement that PegBio signed a Memorandum of Understanding on July 8 with Nasdaq-listed Rani Therapeutics to advance oral formulation development of multiple metabolic innovative assets. Under the agreement, the two parties will leverage Rani's proprietary RaniPill oral biologic drug delivery platform to conduct oral formulation screening and preclinical development across PegBio's obesity and metabolic disease pipeline candidates. The collaboration also explores R&D, manufacturing, and commercialization partnerships for relevant products in markets outside China. The companies plan to screen PegBio's metabolic assets for oral delivery suitability and advance the most promising candidates into clinical development.

PegBio focuses on innovative biologics for chronic and metabolic diseases including Type 2 diabetes, obesity, and NASH, with a tiered pipeline spanning commercialized product Weipeinatide and next-generation long-acting candidates.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)